KR102313757B1 - 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체 - Google Patents

펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체 Download PDF

Info

Publication number
KR102313757B1
KR102313757B1 KR1020167003770A KR20167003770A KR102313757B1 KR 102313757 B1 KR102313757 B1 KR 102313757B1 KR 1020167003770 A KR1020167003770 A KR 1020167003770A KR 20167003770 A KR20167003770 A KR 20167003770A KR 102313757 B1 KR102313757 B1 KR 102313757B1
Authority
KR
South Korea
Prior art keywords
amino
alkyl
carbamoyl
methyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167003770A
Other languages
English (en)
Korean (ko)
Other versions
KR20160031007A (ko
Inventor
리차드 엘. 비어드
티엔 티. 드엉
존 이. 도넬로
비나 비스워나스
마이클 이. 가스트
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20160031007A publication Critical patent/KR20160031007A/ko
Application granted granted Critical
Publication of KR102313757B1 publication Critical patent/KR102313757B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167003770A 2013-07-16 2014-07-10 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체 Expired - Fee Related KR102313757B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846787P 2013-07-16 2013-07-16
US61/846,787 2013-07-16
PCT/US2014/046203 WO2015009545A1 (en) 2013-07-16 2014-07-10 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators

Publications (2)

Publication Number Publication Date
KR20160031007A KR20160031007A (ko) 2016-03-21
KR102313757B1 true KR102313757B1 (ko) 2021-10-18

Family

ID=51230227

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167003770A Expired - Fee Related KR102313757B1 (ko) 2013-07-16 2014-07-10 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체

Country Status (11)

Country Link
US (1) US9428549B2 (https=)
EP (1) EP3022174B1 (https=)
JP (1) JP6653253B2 (https=)
KR (1) KR102313757B1 (https=)
CN (1) CN105377814B (https=)
AU (1) AU2014290618B2 (https=)
CA (1) CA2917811C (https=)
DK (1) DK3022174T3 (https=)
ES (1) ES2708571T3 (https=)
RU (1) RU2696581C2 (https=)
WO (1) WO2015009545A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106518742B (zh) 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
BR112015021392B1 (pt) * 2013-03-06 2021-11-16 Allergan, Inc Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
RU2703725C1 (ru) 2013-11-21 2019-10-22 Аллерган, Инк. Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора
ES2752733T3 (es) 2013-11-28 2020-04-06 Kyorin Seiyaku Kk Derivados de urea deuterados o marcados isotópicamente o sales farmacológicamente aceptables de los mismos útiles como agonistas de FPRL-1
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
CA2948876A1 (en) 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
JP6746613B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
JP6746614B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
CA2992662A1 (en) * 2015-08-05 2017-02-09 Allergan, Inc. Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2968842B2 (ja) * 1994-02-09 1999-11-02 塩野義製薬株式会社 カルバモイルメチルウレア誘導体
WO2013062947A1 (en) 2011-10-26 2013-05-02 Allergan, Inc. Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
HU219913B (hu) * 1994-02-09 2001-09-28 Shionogi And Co. Ltd. Karbamoilezett dipeptidszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
WO1999065932A1 (en) 1998-06-18 1999-12-23 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
WO2003082314A2 (en) * 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
EP1692502A2 (en) * 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
AU2010250789B2 (en) * 2009-05-18 2015-05-14 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists
WO2012074785A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8735622B2 (en) * 2011-11-30 2014-05-27 The Regents Of The University Of Colorado, A Body Corporate Histone demethylase inhibitors and methods for using the same
BR112015021392B1 (pt) * 2013-03-06 2021-11-16 Allergan, Inc Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
BR122017004254B1 (pt) * 2013-03-06 2021-04-13 Allergan, Inc. Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2968842B2 (ja) * 1994-02-09 1999-11-02 塩野義製薬株式会社 カルバモイルメチルウレア誘導体
WO2013062947A1 (en) 2011-10-26 2013-05-02 Allergan, Inc. Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Also Published As

Publication number Publication date
AU2014290618B2 (en) 2018-04-05
DK3022174T3 (da) 2019-01-02
JP6653253B2 (ja) 2020-02-26
CN105377814A (zh) 2016-03-02
US9428549B2 (en) 2016-08-30
US20150025021A1 (en) 2015-01-22
KR20160031007A (ko) 2016-03-21
CA2917811A1 (en) 2015-01-22
RU2016104844A (ru) 2017-08-21
RU2696581C2 (ru) 2019-08-05
JP2016529235A (ja) 2016-09-23
AU2014290618A1 (en) 2016-02-18
ES2708571T3 (es) 2019-04-10
CN105377814B (zh) 2018-04-03
EP3022174A1 (en) 2016-05-25
EP3022174B1 (en) 2018-09-05
WO2015009545A1 (en) 2015-01-22
CA2917811C (en) 2021-08-31

Similar Documents

Publication Publication Date Title
KR102313757B1 (ko) 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체
RU2744577C2 (ru) Амидные производные n-карбамидзамещенных аминокислот как модуляторы формилпептидного рецептора-1 (fprl-1)
RU2627271C2 (ru) Производные арилмочевины в качестве модуляторов n-формилпептидного-1 рецептора (fprl-1)
US8729096B2 (en) Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators
WO2013158597A1 (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
KR102310615B1 (ko) 페닐카바메이트 유도체로서의 포밀 펩타이드 수용체 조절제
WO2015042071A1 (en) Diphenyl urea derivatives as formyl peptide receptor modulators
US9663457B2 (en) Carbamoyl hydrazine derivatives as formyl peptide modulators
HK1225012A1 (en) Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
HK1225012B (en) Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators
HK1228885A (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
HK1228885A1 (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
HK1199622B (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
HK1199639B (en) Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241013

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241013

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241013